{"id":6419,"date":"2025-06-16T16:12:59","date_gmt":"2025-06-16T20:12:59","guid":{"rendered":"https:\/\/cqdm.org\/?p=6419"},"modified":"2026-07-28T15:34:38","modified_gmt":"2026-07-28T19:34:38","slug":"cqdm-welcomes-three-global-pharma-leaders-to-its-consortium","status":"publish","type":"post","link":"https:\/\/cqdm.org\/en\/news-and-events\/cqdm-welcomes-three-global-pharma-leaders-to-its-consortium\/","title":{"rendered":"CQDM Welcomes Three Global Pharma Leaders to Its Consortium"},"content":{"rendered":"\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" width=\"450\" height=\"167\" src=\"https:\/\/cqdm.org\/wp-content\/uploads\/2024\/06\/cqdm_logo_web.png\" alt=\"\" class=\"wp-image-1014\" style=\"width:216px;height:auto\" title=\"\" srcset=\"https:\/\/cqdm.org\/wp-content\/uploads\/2024\/06\/cqdm_logo_web.png 450w, https:\/\/cqdm.org\/wp-content\/uploads\/2024\/06\/cqdm_logo_web-300x111.png 300w\" sizes=\"(max-width: 450px) 100vw, 450px\" \/><\/figure>\n\n\n\n<p class=\"has-text-align-right wp-block-paragraph\"><strong>Announcement<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">CQDM Welcomes Daiichi Sankyo, Ono Pharmaceutical, and Otsuka Pharmaceutical as Newest Members of Its Consortium, Strengthening Its Ability to Connect Canada\u2019s Biopharmaceutical Ecosystem with Global Pharmaceutical Leaders<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>BOSTON, June 17, 2025 <\/strong>\u2013 CQDM is proud to announce the addition of three leading Japanese pharmaceutical companies\u2014<strong>Daiichi Sankyo Co., Ltd.,<\/strong> <strong>Ono Pharmaceutical Co., Ltd.<\/strong>,\u202fand<strong> McQuade Center for Strategic Research and Development (MSRD), an indirect subsidiary of Otsuka Pharmaceutical Co., Ltd.<\/strong>\u2014to its growing biopharmaceutical consortium. This strategic expansion strengthens CQDM\u2019s industry reach and reinforces its mission to accelerate the development of innovative biopharmaceutical technologies in Canada through collaborative research. With this expansion, CQDM\u2019s consortium now includes\u202f<strong>11 global\u202fpharmaceutical<\/strong> companies.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The announcement was made at BIO 2025, bringing together several key stakeholders.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The inclusion of these globally recognized companies brings new perspectives, expertise, and resources to CQDM\u2019s unique collaborative model, which unites industry, academia, and government to support cutting-edge research projects with high translational potential in Canada.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201c<em>We are thrilled to welcome Ono, Otsuka, and Daiichi Sankyo to the CQDM family,<\/em>\u201d said\u202fV\u00e9ronique Dugas, President and CEO of CQDM. \u201c<em>Their commitment to innovation and global health aligns perfectly with our mission. Their participation will not only enhance our industrial network but also open new opportunities for international collaboration and co-development.<\/em>\u201d&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>\u201cWhat sets CQDM apart is its\u202f<strong>exclusive consortium of leading global pharmaceutical companies<\/strong>, which provides a direct bridge between the Canadian life sciences ecosystem and international industry leaders. This model gives Canadian researchers and biotech companies\u202f<strong>unparalleled access to industry insight, mentorship, and commercialization pathways<\/strong>, helping to accelerate the translation of scientific discoveries into real-world therapies\u201d<\/em> said Jesse Paterson, Senior Director, Business development of CQDM&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For more information about CQDM, our pharmaceutical members and how we create links between Canadian research the global pharmaceutical industry, please visit\u202f<a href=\"https:\/\/cqdm.org\/en\/\" target=\"_blank\" rel=\"noreferrer noopener\">www.cqdm.org<\/a>.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a id=\"_msocom_1\"><\/a><\/p>\n\n\n\n<p class=\"has-text-align-center wp-block-paragraph\"><strong>-30 \u2013<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><\/h3>\n\n\n\n<h3 class=\"wp-block-heading\">&nbsp;<strong>About CQDM<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Biopharma Innovation Facilitator<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">CQDM is a not-for-profit biopharmaceutical research consortium whose mission is to support and facilitate collaborative multi-stakeholder research and development aimed at accelerating the translation or transformation of innovative technologies into solutions to unmet medical needs, while generating significant benefits for the Quebec and Canadian economy. For more information, consult our website <a href=\"https:\/\/cqdm.org\/en\/\">cqdm.org<\/a> and join us on <a href=\"https:\/\/x.com\/CQDM_Canada\">Twitter\/X @CQDM_Canada<\/a> and <a href=\"https:\/\/www.linkedin.com\/company\/cqdm\/\" target=\"_blank\" rel=\"noopener\">LinkedIn<\/a>.<br><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>About Daiichi<\/strong> Sankyo<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit<strong><em> <\/em><\/strong><a href=\"https:\/\/can01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Furl.us.m.mimecastprotect.com%2Fs%2FvznDC1wlXMFn1xsGhDhVTDk5%3Fdomain%3Ddaiichisankyo.com&amp;data=05%7C02%7Cjserafino%40cqdm.org%7C19e733ecde284d01524a08dda780f260%7C1bf6ea47c80c40c7ab4e7c53dee6c46b%7C0%7C0%7C638850894465668914%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=wz6AJTa4lMr5JXI1OUx%2FIPP2de5DdCnxRaPI6ABrp4Q%3D&amp;reserved=0\" target=\"_blank\" rel=\"noreferrer noopener\">daiichisankyo.com<\/a>.&nbsp;<br><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>About Ono Pharmaceutical Co., Ltd<\/strong>.<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ono Pharmaceutical Co., Ltd. delivers innovative therapies for patients worldwide. Upholding its philosophy of \u201cDedicated to the Fight against Disease and Pain,\u201d Ono targets areas with unmet medical needs including oncology, immunology, and neurology, and fosters partnerships with academic and biotech organizations to accelerate drug discovery. Through its affiliate, Deciphera Pharmaceuticals, Ono is accelerating clinical development and commercial operations in the US and Europe to drive global business expansion and further its commitment to patient care. For more information, please visit the company&#8217;s website at <a href=\"https:\/\/www.ono-pharma.com\/en\" target=\"_blank\" rel=\"noreferrer noopener\">ono-pharma.com<\/a>.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong><strong>About the McQuade Center for Strategic Research and Development (MSRD) and Otsuka Pharmaceutical Co., Ltd.<\/strong><\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The mission of MSRD is to search for, identify, and fund innovative early-stage research and development programs that can change the landscape of treatments for mental illness, rare neurological diseases, autoimmune diseases and renal disorders. MSRD was established in 2019 by the Otsuka pharmaceutical business in the U.S.&nbsp; For more information about MSRD and Otsuka in North America, visit\u202f<a href=\"https:\/\/msrd-us.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">msrd-us.com<\/a>, <a href=\"https:\/\/www.otsuka-us.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">otsuka-us.com<\/a>, and <a href=\"https:\/\/otsukacanada.com\/\" target=\"_blank\" rel=\"noopener\">otsukacanada.com&nbsp;<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Otsuka Pharmaceutical Co., Ltd., based in Japan, is a total healthcare company that focuses on each individual\u2019s potential to enhance their well-being. Our medical-related business provides treatments and diagnostics for both physical and mental health. Our nutraceutical business supports daily health maintenance and improvement. Otsuka\u2019s unique products and services are based on scientific evidence, under the guidance of our corporate philosophy: <em>Otsuka-people creating new products for better health worldwide<\/em>. For further information, visit <a href=\"http:\/\/www.otsuka.co.jp\/en\/\" target=\"_blank\" rel=\"noreferrer noopener\">www.otsuka.co.jp\/en\/<\/a>&nbsp;<br>&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><\/h3>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-dots\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><br><strong>For further information:<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Julia Serafino<\/strong><br>CQDM Marketing and Communications Manager<br>438-543-9498<br><a href=\"mailto:jserafino@cqdm.org\">jserafino@cqdm.org<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announcement CQDM Welcomes Daiichi Sankyo, Ono Pharmaceutical, and Otsuka Pharmaceutical as Newest Members of Its Consortium, Strengthening Its Ability to Connect Canada\u2019s Biopharmaceutical Ecosystem with Global Pharmaceutical Leaders BOSTON, June 17, 2025 \u2013 CQDM is proud to announce the addition of three leading Japanese pharmaceutical companies\u2014Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd.,\u202fand McQuade Center&hellip;<\/p>\n","protected":false},"author":2,"featured_media":6499,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6419","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-our-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/6419","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/comments?post=6419"}],"version-history":[{"count":6,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/6419\/revisions"}],"predecessor-version":[{"id":8199,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/6419\/revisions\/8199"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media\/6499"}],"wp:attachment":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media?parent=6419"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/categories?post=6419"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/tags?post=6419"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}